<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954040</url>
  </required_header>
  <id_info>
    <org_study_id>AMBUCOV</org_study_id>
    <nct_id>NCT04954040</nct_id>
  </id_info>
  <brief_title>Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19</brief_title>
  <acronym>AMBUCOV</acronym>
  <official_title>Clinical Trial for the Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centered, randomized, open label clinical trial to study the safety and effectivity of&#xD;
      hydroxychloroquine + azithromycin to treat COVID-19 symptoms in primary care patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the patient group treated with hydroxychloroquine + azithromycin we expect to find a&#xD;
      diminution of 20% or more regarding the evolution of acute respiratory syndrome, as opposed&#xD;
      to patients who have not been treated with these medicines.&#xD;
&#xD;
      To date, there is no shown effective treatment regime for acute respiratory distress caused&#xD;
      by COVID-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>From randomization until patient's hospitalization happens, assessed up to 28 days.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU admission</measure>
    <time_frame>From date of randomization until ICU admission as a result of COVID19, assessed up to 28 days.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>From randomization until death by any cause related to COVID19, assessed up to 28 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Evolution</measure>
    <time_frame>From randomization until healing, hospitalization or death. Symptoms will be evaluated every 24 hours for a minimum of 10 days and a maximum 28 days.</time_frame>
    <description>Clinical evolution will be evaluated through the following symptoms: fever, cough, dyspnoea, diarrhea, loss of smell.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine + Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin. 1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0&#xD;
Oral intake in all cases. Pills will be taken simultaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC (Standard of Care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SOC for symptoms treatment&#xD;
Acetaminophen or Metamizole, 1-1-1 Antitussives if needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Pill + Azithromycin Pill</intervention_name>
    <description>Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.&#xD;
1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0</description>
    <arm_group_label>Hydroxychloroquine + Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>Acetaminophen or Metamizole. Antitussives if needed.</description>
    <arm_group_label>SOC (Standard of Care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with positive semi-quantitative PCR and COVID19 symptoms (fever, cough,&#xD;
             diarrhea, dyspnoea, loss of smell).&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Retinal degeneration.&#xD;
&#xD;
          -  Congenital or acquired long QT syndrome.&#xD;
&#xD;
          -  Advanced liver failure.&#xD;
&#xD;
          -  Renal insufficiency (incompatible with creatinine clearance less than 50 mL /minute).&#xD;
&#xD;
          -  Allergic to hydroxychloroquine or azithromycin.&#xD;
&#xD;
          -  Serious interaction with the drugs used.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Men and women in fertile and sexually active periods, who do not accept a highly&#xD;
             effective contraceptive method.&#xD;
&#xD;
          -  Inability to follow study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Miguel Luque Pineda</last_name>
    <phone>+34 671 596 070</phone>
    <email>uicec@imibic.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Salud Priego de Córdoba</name>
      <address>
        <city>Priego de Córdoba</city>
        <state>Córdoba</state>
        <zip>14800</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Gallardo de Ávila, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute respiratory syndrome</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID19</keyword>
  <keyword>hydroxychloroquine</keyword>
  <keyword>azithromycin</keyword>
  <keyword>COVID19 symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared after the study concludes and results are published</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>When study is published.</ipd_time_frame>
    <ipd_access_criteria>Sending request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

